DE69408539T2 - Zusammensetzungen und methoden zur verhüttung der sauerstofftoxizität mittels nitroxiden - Google Patents
Zusammensetzungen und methoden zur verhüttung der sauerstofftoxizität mittels nitroxidenInfo
- Publication number
- DE69408539T2 DE69408539T2 DE69408539T DE69408539T DE69408539T2 DE 69408539 T2 DE69408539 T2 DE 69408539T2 DE 69408539 T DE69408539 T DE 69408539T DE 69408539 T DE69408539 T DE 69408539T DE 69408539 T2 DE69408539 T2 DE 69408539T2
- Authority
- DE
- Germany
- Prior art keywords
- nitroxides
- prevention
- methods
- compositions
- macromolecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10754393A | 1993-08-16 | 1993-08-16 | |
US08/291,590 US5591710A (en) | 1993-08-16 | 1994-08-15 | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
PCT/US1994/009246 WO1995005397A1 (en) | 1993-08-16 | 1994-08-16 | Composition and methods using nitroxides to avoid oxygen toxicity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69408539D1 DE69408539D1 (de) | 1998-03-19 |
DE69408539T2 true DE69408539T2 (de) | 1998-06-18 |
Family
ID=22317141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69408539T Expired - Fee Related DE69408539T2 (de) | 1993-08-16 | 1994-08-16 | Zusammensetzungen und methoden zur verhüttung der sauerstofftoxizität mittels nitroxiden |
Country Status (13)
Country | Link |
---|---|
US (5) | US5591710A (de) |
EP (2) | EP0714407B1 (de) |
JP (1) | JP3628019B2 (de) |
CN (3) | CN1046635C (de) |
AT (1) | ATE163186T1 (de) |
CA (1) | CA2169178A1 (de) |
DE (1) | DE69408539T2 (de) |
DK (1) | DK0714407T3 (de) |
ES (1) | ES2114227T3 (de) |
GR (1) | GR3026609T3 (de) |
HK (1) | HK1007858A1 (de) |
TW (2) | TW381022B (de) |
WO (1) | WO1995005397A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605619B1 (en) * | 1992-03-20 | 2003-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxides as protectors against oxidatives stress |
TW381022B (en) * | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
US5840701A (en) * | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
SG95590A1 (en) * | 1995-03-31 | 2003-04-23 | Synzyme Technologies Inc | Compositions and method utilizing nitroxides in combination with biocompatible macromolecules |
AU693354B2 (en) * | 1995-04-10 | 1998-06-25 | Baxter International Inc. | The use of cross-linked hemoglobin in treating subarachnoid hemorrhage |
DE19514088A1 (de) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen |
US6149891A (en) * | 1995-05-31 | 2000-11-21 | Israel Humanitarian Foundation Ltd. | X-ray contrast medium and method for protecting against harmful effects thereof |
US6197745B1 (en) * | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
US6627738B2 (en) * | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
US6911427B1 (en) | 1995-09-15 | 2005-06-28 | Duke University | No-modified hemoglobins and uses therefore |
UA64710C2 (en) * | 1996-03-28 | 2004-03-15 | Aqueous solution of polymerized hemoglobin (variants), method for its manufacture (variants) and method of infusion | |
US6547781B1 (en) * | 1996-04-09 | 2003-04-15 | Cynsure, Inc. | Ultra-long flashlamp-excited pulse dye laser for therapy and method therefor |
AU6150298A (en) * | 1997-02-06 | 1998-08-26 | Duke University Medical Center | No-modified hemoglobins and uses therefor |
US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
US6054427A (en) * | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
CH694074A5 (de) * | 1997-08-16 | 2004-07-15 | Orthogen Gentechnologie Gmbh | Verfahren zur Herstellung von therapeutisch wirksamen Proteinen. |
US6096759A (en) * | 1997-09-19 | 2000-08-01 | Georgetown University | Method for treating essential hypertension |
US6347627B1 (en) * | 1998-04-23 | 2002-02-19 | Pioneer Inventions, Inc. | Nitrous oxide based oxygen supply system |
JP2000230000A (ja) * | 1999-02-08 | 2000-08-22 | Hokkaido Univ | 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体 |
CA2266174A1 (en) * | 1999-03-18 | 2000-09-18 | Hemosol Inc. | Hemoglobin-antioxidant conjugates |
US6894150B1 (en) | 1999-10-01 | 2005-05-17 | Ross Walden Tye | Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin |
EP2292657A1 (de) * | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Hämoglobinzusammensetzungen mit verringerten Nebenwirkungen |
DE10011163A1 (de) * | 2000-02-28 | 2001-09-13 | Ew Handels & Consulting Gmbh | Verfahren zur Diagnose und/oder Überwachung physiologischer oder pathologischer Veränderungen im menschlichen oder tierischen Körper und ESR-Spektrometer zur Durchführung des Verfahrens |
AU2001293064A1 (en) * | 2000-09-26 | 2002-04-08 | Georgetown University | Use of nitroxides for the treatment of vascular disorders in a diabetic mammal |
US20030045461A1 (en) * | 2001-09-06 | 2003-03-06 | Jen-Chang Hsia | Composition and methods of esterified nitroxides gated with carboxylic acids |
US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
US20030153491A1 (en) * | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
JP3912206B2 (ja) * | 2002-07-05 | 2007-05-09 | 株式会社日立製作所 | 筒内直接燃料噴射装置用燃料ポンプ |
EP1534269B1 (de) * | 2002-07-19 | 2013-10-30 | The General Hospital Corporation | Oxim-konjugate und verfahren zu ihrer bildung und verwendung |
AU2003278565A1 (en) * | 2002-10-25 | 2004-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
CN100431602C (zh) * | 2003-01-29 | 2008-11-12 | 北原实验室有限公司 | 具有低量四聚体的聚合血红蛋白溶液及制备方法 |
AU2004233862A1 (en) * | 2003-04-25 | 2004-11-11 | Mitos Pharmaceuticals, Inc. | Prophylactic pretreatment with antioxidants |
EP1660133B1 (de) * | 2003-05-15 | 2018-04-18 | Therapure Biopharma Inc. | Gezielte abgabe von antiviralmitteln durch hämoglobin-konjugierung |
US7589107B2 (en) * | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
US20050130906A1 (en) * | 2003-11-20 | 2005-06-16 | Matier William L. | Amelioration of macular degeneration and other ophthalmic diseases |
WO2006127592A2 (en) * | 2005-05-26 | 2006-11-30 | Othera Pharmaceuticals, Inc. | Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts |
DE102005031206A1 (de) * | 2005-07-01 | 2007-01-11 | Rovi Gmbh & Co. Kosmetische Rohstoffe Kg | Verfahren zur Untersuchung von Liposomen |
US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
WO2008021577A2 (en) | 2006-01-24 | 2008-02-21 | The Board Of Trustees Of The University Of Illinois | Polymerized hemoglobin media and its use in isolation and transplantation of islet cells |
US20070197599A1 (en) * | 2006-02-02 | 2007-08-23 | Matier William L | Hydroxylamines and derivatives as anti-angiogenic agents |
US20070197593A1 (en) * | 2006-02-22 | 2007-08-23 | Matier William L | Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver |
US7494974B2 (en) * | 2006-10-24 | 2009-02-24 | Ikor, Inc. | Carboxymethylated cross-linked tetrameric hemoglobin |
US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
WO2008063868A2 (en) | 2006-11-07 | 2008-05-29 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
CA2678363A1 (en) * | 2007-02-16 | 2008-08-21 | Othera Holding, Inc. | Drug resistance reversal in neoplastic disease |
CA2679066A1 (en) | 2007-02-22 | 2008-08-28 | Othera Holding, Inc. | Hydroxylamine compounds and methods of their use |
US8273857B2 (en) * | 2009-09-22 | 2012-09-25 | Jen-Chang Hsia | Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine |
US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
JP6389125B2 (ja) | 2011-11-07 | 2018-09-12 | ザ ジェネラル ホスピタル コーポレイション | 赤血球の処理法 |
CN102559592B (zh) * | 2011-12-26 | 2014-04-16 | 四川农业大学 | 一种鱼红细胞氧化应激模型的建立方法 |
MX358784B (es) * | 2012-04-03 | 2018-09-04 | Sangart Inc | Compuestos de nitroxilo activados con succinimida y metodos para el uso de los mismos para nitroxilacion de proteinas. |
PL2968478T3 (pl) * | 2013-03-15 | 2019-01-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Kompozycje i sposoby do leczenia karboksyhemoglobinemii |
AU2018304174A1 (en) | 2017-07-18 | 2020-02-06 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
US10597597B1 (en) | 2018-09-12 | 2020-03-24 | Exxonmobil Research And Engineering Company | Fuel high temperature antioxidant additive |
US11136516B2 (en) | 2018-12-07 | 2021-10-05 | Exxonmobil Research And Engineering Company | Motor gasoline with improved octane and method of use |
WO2020117522A1 (en) | 2018-12-07 | 2020-06-11 | Exxonmobil Research And Engineering Company | Fuel high temperature antioxidant additive |
CN112546206A (zh) * | 2020-12-30 | 2021-03-26 | 云锦华彰(北京)生物科技有限公司 | 一种人源性血红蛋白类氧载体的制备方法及其产品和应用 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959287A (en) * | 1972-07-10 | 1976-05-25 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement |
DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4136093A (en) * | 1976-04-23 | 1979-01-23 | Biotest-Serum-Institut Gmbh | Hemoglobin preparation with increased oxygen release |
US4240797A (en) * | 1977-10-18 | 1980-12-23 | The Governing Council Of The University Of Toronto | Assay for reserve bilirubin binding capacity |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5716815A (en) * | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
US4563349A (en) * | 1980-07-30 | 1986-01-07 | Takeda Chemical Industries, Ltd. | Superoxide dismutase, its immobilized form, and their production and use |
JPS5739854A (en) * | 1980-08-25 | 1982-03-05 | Terumo Corp | Hollow fiber type artificial lung building in heat exchanger |
US4401652A (en) * | 1980-12-31 | 1983-08-30 | Allied Corporation | Process for the preparation of stroma-free hemoglobin solutions |
JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4473496A (en) * | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
US4473494A (en) * | 1983-05-04 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Preparation of stroma-free, non-heme protein-free hemoglobin |
DE3328365A1 (de) * | 1983-08-03 | 1985-02-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue diagnostische mittel |
US4831012A (en) * | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
US4622294A (en) * | 1985-02-08 | 1986-11-11 | Kung Viola T | Liposome immunoassay reagent and method |
US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
CA1244349A (en) * | 1985-06-26 | 1988-11-08 | Jen-Chang Hsia | Purification of hemoglobin and modified hemoglobin by affinity chromatography |
GB8522535D0 (en) * | 1985-09-11 | 1985-10-16 | Amersham Int Plc | Contrast agent |
GB8600582D0 (en) * | 1986-01-10 | 1986-02-19 | Ca Minister Nat Defence | Purifying biological materials |
EP0235526A3 (de) * | 1986-01-29 | 1988-03-23 | Leipziger Arzneimittelwerk GmbH | Aktivierte Polymerfestkörper und Verfahren zu ihrer Herstellung |
US5104641A (en) * | 1986-03-07 | 1992-04-14 | M.R.I., Inc. | Nitroxide NMR contrast enhancing agents and their use in NMR imaging |
US5256397A (en) * | 1986-03-07 | 1993-10-26 | M.R.I., Inc. | 2,2,5,5-tetrasubstituted-pyrrolidine-1-oxyl compounds useful as MRI agents |
US4834964A (en) * | 1986-03-07 | 1989-05-30 | M.R.I., Inc. | Use of charged nitroxides as NMR image enhancing agents for CSF |
US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
FR2602774B1 (fr) * | 1986-07-29 | 1990-10-19 | Atta | Nouvelles molecules amphiphiles polyhydroxylees et perfluoroalkylees ayant des proprietes tensioactives |
US4911929A (en) * | 1986-08-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Blood substitute comprising liposome-encapsulated hemoglobin |
DE3636590A1 (de) * | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | Blutersatzmittel |
US4863717A (en) * | 1986-11-10 | 1989-09-05 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging |
WO1988005044A1 (en) * | 1986-12-29 | 1988-07-14 | Pharmacia Ab | Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage |
GB8710598D0 (en) * | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
DE68917946T2 (de) * | 1988-01-29 | 1995-01-05 | Peter H Proctor | Haarwachstumanregung mit Nitroxyd und anderen Radikalen. |
GB8808305D0 (en) * | 1988-04-08 | 1988-05-11 | Nycomed As | Compositions |
US5023072A (en) * | 1988-08-10 | 1991-06-11 | University Of New Mexico | Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract |
US5061688A (en) * | 1988-08-19 | 1991-10-29 | Illinois Institute Of Technology | Hemoglobin multiple emulsion |
US5149425A (en) * | 1988-11-09 | 1992-09-22 | Chembiomed, Ltd. | Affinity supports for hemoperfusion |
US5314681A (en) * | 1988-12-23 | 1994-05-24 | Nycomed Innovation Ab | Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging |
US5080645A (en) * | 1989-10-31 | 1992-01-14 | Hanig Joseph P | Procedure for reducing the body burden of HIV (AIDS) and other blood borne infections |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
EP0787492B1 (de) * | 1990-03-16 | 2003-09-17 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | Verwendung von Nitroxiden und Oxazolidinen zum Schutz ionisierender Strahlung und oxidativem Stress |
US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
US5114932A (en) * | 1990-11-30 | 1992-05-19 | Runge Thomas M | Hyperosmolar oxyreplete hemosubstitute |
US5290919A (en) * | 1992-08-28 | 1994-03-01 | The University Of Maryland Baltimore | Hemoglobin intramolecularly cross-linked with trivalent reagents |
US5407657A (en) * | 1992-09-22 | 1995-04-18 | Unger; Evan C. | Hybrid magnetic resonance contrast agents |
US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5494030A (en) * | 1993-08-12 | 1996-02-27 | Trustees Of Dartmouth College | Apparatus and methodology for determining oxygen in biological systems |
TW381022B (en) * | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
US5741893A (en) * | 1993-08-16 | 1998-04-21 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
-
1993
- 1993-09-09 TW TW082107408A patent/TW381022B/zh active
-
1994
- 1994-08-15 US US08/291,590 patent/US5591710A/en not_active Expired - Lifetime
- 1994-08-16 DK DK94927922T patent/DK0714407T3/da active
- 1994-08-16 EP EP94927922A patent/EP0714407B1/de not_active Expired - Lifetime
- 1994-08-16 EP EP96116519A patent/EP0770627A1/de not_active Withdrawn
- 1994-08-16 WO PCT/US1994/009246 patent/WO1995005397A1/en active IP Right Grant
- 1994-08-16 AT AT94927922T patent/ATE163186T1/de not_active IP Right Cessation
- 1994-08-16 JP JP50714895A patent/JP3628019B2/ja not_active Expired - Fee Related
- 1994-08-16 CN CN94193809A patent/CN1046635C/zh not_active Expired - Fee Related
- 1994-08-16 ES ES94927922T patent/ES2114227T3/es not_active Expired - Lifetime
- 1994-08-16 CA CA002169178A patent/CA2169178A1/en not_active Abandoned
- 1994-08-16 DE DE69408539T patent/DE69408539T2/de not_active Expired - Fee Related
-
1995
- 1995-10-12 US US08/541,228 patent/US5811005A/en not_active Expired - Fee Related
-
1997
- 1997-01-06 US US08/777,274 patent/US5789376A/en not_active Expired - Lifetime
-
1998
- 1998-04-10 GR GR980400805T patent/GR3026609T3/el unknown
- 1998-06-26 HK HK98106880A patent/HK1007858A1/xx not_active IP Right Cessation
- 1998-07-30 TW TW087112426A patent/TW529949B/zh active
- 1998-08-03 US US09/128,375 patent/US6048967A/en not_active Expired - Lifetime
-
1999
- 1999-02-15 CN CN99102347A patent/CN1228962A/zh active Pending
- 1999-02-15 CN CN99102348A patent/CN1229677A/zh active Pending
-
2000
- 2000-04-10 US US09/545,661 patent/US6323175B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2114227T3 (es) | 1998-05-16 |
JP3628019B2 (ja) | 2005-03-09 |
US5591710A (en) | 1997-01-07 |
TW381022B (en) | 2000-02-01 |
EP0770627A1 (de) | 1997-05-02 |
GR3026609T3 (en) | 1998-07-31 |
ATE163186T1 (de) | 1998-02-15 |
CA2169178A1 (en) | 1995-02-23 |
JPH09501681A (ja) | 1997-02-18 |
TW529949B (en) | 2003-05-01 |
CN1133050A (zh) | 1996-10-09 |
EP0714407A1 (de) | 1996-06-05 |
US5789376A (en) | 1998-08-04 |
DK0714407T3 (da) | 1998-09-28 |
DE69408539D1 (de) | 1998-03-19 |
EP0714407B1 (de) | 1998-02-11 |
US6048967A (en) | 2000-04-11 |
US5811005A (en) | 1998-09-22 |
CN1229677A (zh) | 1999-09-29 |
WO1995005397A1 (en) | 1995-02-23 |
US6323175B1 (en) | 2001-11-27 |
CN1228962A (zh) | 1999-09-22 |
CN1046635C (zh) | 1999-11-24 |
HK1007858A1 (en) | 1999-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69408539D1 (de) | Zusammensetzungen und methoden zur verhüttung der sauerstofftoxizität mittels nitroxiden | |
ATE395357T1 (de) | Verfahren und zusammensetzungen zur vermeidung und behandlung von anämie | |
ATE291351T1 (de) | Superoxiddismutase memetika | |
PL320637A1 (en) | Anticoagulants | |
DE60036169D1 (de) | Methoden zur Behandlung der Hautpigmentierung | |
DE69211598T2 (de) | Verwendung von Zinkionen zur Behandlung der Periodontitis | |
DE69131589T2 (de) | Ribosomen-inaktivierende Proteine, inaktive Vorläuferformen derselben, Verfahren zur Herstellung und eine Methode zur Nutzung | |
DE3679128D1 (de) | Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben. | |
DE59405376D1 (de) | Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten | |
ATE84721T1 (de) | Physiologisch wirksame produkte, verfahren zur herstellung und zusammensetzung. | |
DE69311260D1 (de) | Verfahren zur Herstellung von (E)-Alkoximino- oder Hydroxyiminoacetamidverbindungen und Zwischenprodukte | |
ATE293976T1 (de) | Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen | |
MX9704050A (es) | P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n. | |
ATE272648T1 (de) | Glycokonjugate von 20(s)-camptothecin | |
DE59209133D1 (de) | Verfahren zur Herstellung eines virussicheren Thrombinkonzentrates | |
DE1155677T1 (de) | Methoden und Zusammensetzungen zur Inhibierung der Radikal initierten Polymerisation in der Haut und dem Haar | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
ATE150018T1 (de) | Imidazolyl-substituierte phenylessigsäureprolinamide | |
DE69924741D1 (de) | Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur vorbeugung und behandlung von parodontitis | |
PT1255734E (pt) | Derivados de isatina com actividade neurotrofica | |
DE69531554D1 (de) | Verwendung von inosittriphosphat zur herstellung von arzneimitteln | |
DE69011377D1 (de) | Behandlung von alkoholischen Getränken. | |
ES2093040T3 (es) | Hidroximetil-indolizidinas y quinolizidinas. | |
DE69431187T2 (de) | 14-substituierte marcfortine und derivate als antiparasitäre mittel | |
PL375299A1 (en) | 3-heterocyclyl substituted benzoic acid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |